KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenueProperty, Plant & Equipment, Net BreakdownR&D As A %R&D SegregationRevenueRevenue By Customer TypeRevenue By Customer Type %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue By SegmentRevenue By Segment %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2025)

Acadia Pharmaceuticals has reported Gross Profit over the past 10 years, most recently at $257.8 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 8.4% year-over-year to $257.8 million; the TTM value through Dec 2025 reached $982.5 million, up 12.16%, while the annual FY2025 figure was $982.5 million, 12.16% up from the prior year.
  • Gross Profit for Q4 2025 was $257.8 million at Acadia Pharmaceuticals, roughly flat from $257.0 million in the prior quarter.
  • Over five years, Gross Profit peaked at $257.8 million in Q4 2025 and troughed at $104.4 million in Q1 2021.
  • A 5-year average of $175.8 million and a median of $170.3 million in 2023 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: increased 0.51% in 2022 and later skyrocketed 58.98% in 2023.
  • Year by year, Gross Profit stood at $120.0 million in 2021, then increased by 11.72% to $134.1 million in 2022, then soared by 58.98% to $213.2 million in 2023, then rose by 11.56% to $237.8 million in 2024, then rose by 8.4% to $257.8 million in 2025.
  • Business Quant data shows Gross Profit for ACAD at $257.8 million in Q4 2025, $257.0 million in Q3 2025, and $243.8 million in Q2 2025.